Showing 4581-4590 of 20465 results for "".
- Ludient Launches in US With AI-Driven Approach to Clinical Skincarehttps://reachmd.com/news/ludient-launches-in-us-with-ai-driven-approach-to-clinical-skincare/2487480/Ludient, a clinical skincare brand developed by lululab, has officially launched in the United States, introducing an artificial intelligence (AI)-driven approach to skincare product development. According to the company, Ludient’s platform is powered by its proprietary luluTI™ technology,
- Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Neoplasiahttps://reachmd.com/news/avelumab-methotrexate-gestational-trophoblastic-neoplasia/2487473/Key Takeaways hCG normalization was observed in 25 of 26 assessable patients, with a median 3.4 months to normalization. One dose-limiting event occurred, 6 patients had grade 2 or higher immune-related treatment-related adverse events, no grade 4 or h
- Telehealth Rehabilitation and Quality of Life After Mechanical Ventilationhttps://reachmd.com/news/telehealth-rehab-quality-life-mechanical-ventilation/2487478/Key Takeaways An integrated telehealth rehabilitation strategy was associated with higher quality-of-life utility at 90 days after discharge. Mortality, ventilation duration, days alive and free of hospital, and ordinal clinical status also moved in a
- COVID History Linked to New Allergic Disease Riskhttps://reachmd.com/news/covid-history-linked-to-new-allergic-disease-risk/2487429/As the long-term consequences of COVID-19 continue to come into focus, emerging evidence suggests that the virus may leave behind more than respiratory or cardiovascular complications. New research is adding to a growing body of literature indicating that SARS-CoV-2 infection may also incre
- Prostate MRI Screening Standards and Test Performancehttps://reachmd.com/news/prostate-mri-screening-standards-and-test-performance/2487450/Key Takeaways Across six studies involving 1,919 participants, 1,426 underwent upfront screening MRI, with pooled estimates for biopsy referral, clinically significant cancer detection, and positive predictive value. If MRI was used for screening, cand
- Adjuvant Selpercatinib in Early-Stage RET Fusion-Positive NSCLChttps://reachmd.com/news/adjuvant-selpercatinib-in-early-stage-ret-fusion-positive-nsclc/2487453/Key Takeaways In stage II or IIIA disease, 2-year investigator-assessed event-free survival was higher with selpercatinib than with placebo. Across the broader stage IB, II, or IIIA population, event-free survival also favored selpercatinib over placeb
- Diffusive Versus Convective CRRT in AKIhttps://reachmd.com/news/diffusive-versus-convective-crrt-in-aki/2487455/Key Takeaways No advantage was observed for diffusive versus convective therapy for ICU mortality, 28-day mortality, renal recovery, or ICU length of stay. Filter clotting was less frequent with diffusive therapy, and the authors linked this to longer
- Lifestyle Program Sustains Metabolic Syndrome Remissionhttps://reachmd.com/news/lifestyle-program-sustains-metabolic-syndrome-remission/2487463/Key Takeaways Higher metabolic syndrome remission was observed with the intervention at both early and longer-term follow-up. Selected secondary differences remained at 24 months, including fasting glucose and several lifestyle measures. No ad
- Lumateperone Monotherapy in Bipolar Depression Falls Short on Efficacyhttps://reachmd.com/news/lumateperone-monotherapy-in-bipolar-depression-falls-short-on-efficacy/2487448/Key Takeaways Neither lumateperone 28 mg nor 42 mg showed significant improvement over placebo on the primary MADRS endpoint at Day 43. The key secondary endpoint of time to first sustained response also did not differ meaningfully from placebo for eit
- Preoperative Nonopioid Analgesia Lowers Opioid Use After Arthroscopyhttps://reachmd.com/news/preoperative-nonopioid-analgesia-lowers-opioid-use-after-arthroscopy/2487452/Key Takeaways Preoperative nonopioid medication was associated with a small overall reduction in opioid consumption during the first postoperative day. Statistically significant opioid-sparing effects were reported for COX-2 inhibitors and gabapentin,